Osimertinib’s selective cytotoxicity against CD34+ cells suggests that combining it with imatinib might offer a promising strategy to address BCR-ABL-independent mechanisms of resistance in CML [32,33,34]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.